Article

Supplementary Material: MULTISCALE ANALYSIS AND VALIDATION OF EFFECTIVE DRUG COMBINATIONS TARGETING DRIVER KRAS MUTATIONS IN NON-SMALL CELL LUNG CANCER

Liana Bruggemann[1], Zackary Falls [1], William Mangione[1], Stanley A Schwartz[2], Sebastiano Battaglia[3], Ravikumar Aalinkeel[2], Supriya D. Mahajan[2,*], Ram Samudrala[1,*]

[1] Department of Biomedical Informatics, University at Buffalo;
[2] Department of Medicine, University at Buffalo;
[3] Roswell Park Cancer Institute, Buffalo NY;
* Correspondence: smahajan@buffalo.edu; ram@compbio.org



Figure S1. GI50 for BAY-293. The concentration (horizontal axis) of osimertinb is plotted against the H1792 cellular inhibition percentage (vertical axis). The GI50, or concentration required for 50% cellular inhibition, for BAY-293 was unable to be calculated with Graphpad prism 9.0, as there was not a strong enough effect. This indicates that BAY-293 is not effective at decreasing cellular proliferation in H1792 as a single agent.

Citation: Bruggemann et al. Multiscale prediction of drug combinations targeting driver KRAS mutations. *Journal Not Specified* **2022**, *1*, 0. https://doi.org/

Academic Editor: Firstname Lastname

Received:
Accepted:
Published:



Figure S2. GI50 for ARS-1620. The concentration (horizontal axis) of osimertinb is plotted against the H1792 cellular inhibition percentage (vertical axis). The GI50, or concentration required for 50% cellular inhibition, for ARS-1620 was unable to be calculated with Graphpad prism 9.0, as there was not a strong enough effect. This indicates that ARS-1620 is not effective at decreasing cellular proliferation in H1792 as a single agent.



Figure S3. Cellular proliferation for PC-3 with ARS-1620 + osimertinib. The concentration (horizontal axis) of osimertinb and ARS-1620 is plotted against the PC-3 cellular inhibition percentage (vertical axis). The third strongest treatment condition was slightly significant ($p < 0.01$). This indicates that the osimertinib and ARS-1620 combination does not inhibit cellular proliferation in PC-3 relative to the untreated control.



Figure S4. Cellular proliferation for PC-3 with BAY-293 + osimertinib. The concentration (horizontal axis) of osimertinb and BAY-293 is plotted against the PC-3 cellular inhibition percentage (vertical axis). The three strongest treatment conditions were all significantly higher ($p < 0.001$) compared to the untreated control. This indicates that while the osimertinib and BAY-293 combination shows some effect at inhibiting PC-3 cellular proliferation, it is far less than the effect observed with H1792.